ArticleHistology and histopathology2026
Astragalus polysaccharide protects against neuron degeneration and mitochondrial dysfunction in Parkinson's disease by upregulating CEND1.
Article in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundParkinson's disease (PD) is a chronic neurodegenerative disorder featuring dopaminergic neuron loss, which is associated with mitochondrial dysfunction. Astragalus polysaccharide (APS) extracted from
methodsSH-SY5Y cells were treated with 6-hydroxydopamine (6-OHDA) to induce the
results6-OHDA downregulated CEND1 expression in SH-SY5Y cells and PD mice, which, however, was reversed after APS treatment. CEND1 knockdown aggravated while CEND1 overexpression ameliorated 6-OHDA-induced SH-SY5Y cell injury, apoptosis, ROS production, and mitochondrial dysfunction. The preventive effects of CEND1 upregulation against 6-OHDA-induced neuron degeneration and mitochondrial dysfunction were attributed to the activation of the PI3K/AKT and AMPK/SIRT1/PGC-1α signaling pathways. Besides, APS alleviated 6-OHDA-induced SH-SY5Y cell injury and mitochondrial dysfunction, while silencing of CEND1 abrogated the neuroprotective effects of APS
conclusionAPS exerts its neuroprotective effects in PD by preventing mitochondrial dysfunction through increasing CEND1 expression.
Indexed as
Identifiers
41537354What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.